US APPEALS COURT ISSUES A TEMPORARY INJUNCTION PENDING APPEAL AGAINST DISTRIBUTION OF GENERIC PULMICORT RESPULES®(Budesonide Inhalation Suspension)
AstraZeneca today announced that the US Court of Appeals for the Federal Circuit issued a temporary injunction blocking generic manufacturers from distributing generic versions of PULMICORT RESPULES in the US until the Court rules on AstraZeneca’s appeal of a District Court decision that found one patent protecting the product to be invalid and another patent not infringed. As a condition of the injunction, the Court has also ordered that AstraZeneca post a bond in the amount of $72 million. “We intend to vigorously defend the intellectual property rights protecting PULMICORT RESPULES.”